Merck & Co., Inc.
Euronext ParisTotal Valuation
Merck & Co., Inc. carries a market capitalization of 260.61B, placing it among publicly traded companies globally. Its enterprise value stands at 43.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 260.61B |
| Enterprise Value | 43.47B |
Share Statistics
Merck & Co., Inc. currently has 2.47B shares outstanding.
| Shares Outstanding | 2.47B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
On an enterprise value basis, Merck & Co., Inc. trades at an EV/EBITDA multiple of 2.26 and an EV/FCF ratio of 2.28. The EV/Sales ratio of 0.66 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 3.35 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.66 |
| EV / EBITDA | 2.26 |
| EV / EBIT | 3.35 |
| EV / FCF | 2.28 |
Financial Position
Merck & Co., Inc. maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.94, indicating elevated leverage, while an interest coverage ratio of 12.63 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.30 |
| Quick Ratio | 0.66 |
| Debt / Equity | 106.94 |
| Debt / EBITDA | 2.56 |
| Interest Coverage | 12.63 |
Financial Efficiency
Merck & Co., Inc. posts a return on equity of 13.10 and a return on invested capital of 10.64.
| Return on Equity (ROE) | 13.10 |
| Return on Assets (ROA) | 7.33 |
| Return on Invested Capital (ROIC) | 10.64 |
| Return on Capital Employed (ROCE) | 9.17 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.71 |
Taxes
Over the trailing twelve months, Merck & Co., Inc. has paid 2.70B in income taxes, reflecting an effective tax rate of 23.18.
| Income Tax | 2.70B |
| Effective Tax Rate | 23.18 |
Stock Price Statistics
Merck & Co., Inc.'s stock has gained approximately 11.18421% over the past 52 weeks. The 50-day moving average sits at 101.40, while the 200-day moving average is 101.40.
| Beta (5Y) | N/A |
| 52-Week Price Change | 11.18421% |
| 50-Day Moving Average | 101.40 |
| 200-Day Moving Average | 101.40 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached 19.22B, while operating income came in at 12.97B.
| Revenue | 65.77B |
| Gross Profit | 48.61B |
| Operating Income | 12.97B |
| Pretax Income | 11.63B |
| Net Income | 8.94B |
| EBITDA | 19.22B |
| EBIT | 12.97B |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Merck & Co., Inc. holds 5.70B in cash and equivalents against 49.12B in total debt, resulting in a net debt position of 43.79B. Total book value stands at 68.51B, with working capital of 8.07B providing operational flexibility.
| Cash & Cash Equivalents | 5.70B |
| Total Debt | 49.12B |
| Net Debt | 43.79B |
| Equity (Book Value) | 68.51B |
| Book Value Per Share | N/A |
| Working Capital | 8.07B |
Cash Flow
Merck & Co., Inc. produced 17.89B in operating cash flow over the past twelve months.
| Operating Cash Flow | 17.89B |
| Capital Expenditures | N/A |
| Free Cash Flow | 17.89B |
| FCF Per Share | N/A |
Margins
Merck & Co., Inc. operates with a gross margin of 73.91, reflecting its pricing power and cost economics. The operating margin of 19.72 and net profit margin of 13.59 provide insight into operational efficiency.
| Gross Margin | 73.91 |
| Operating Margin | 19.72 |
| Pretax Margin | 17.68 |
| Profit Margin | 13.59 |
| EBITDA Margin | 29.23 |
Dividends & Yields
The company's payout ratio of 92.14 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 92.14 |
| Shareholder Yield | N/A |
| FCF Yield | N/A |
Scores
Merck & Co., Inc. posts an Altman Z-Score of 2.60, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.60 |